Search
- Nov 2, 2023
Ambrx's CEO & CSO discuss the ADC space and recent #ESMO23 data
Dan O'Connor and Shawn Zhang describe Ambrx's HER2 and PSMA targeting antibody-drug conjugate programs.
Also look for unique social pages for BiotechTV U.
#1. Ultragenyx's Emil Kakkis on Angelman syndrome data, rare disease treatment modalities, and more
#2. The CEO of Madrigal on the launch of Rezdiffra for NASH liver disease
#3. Sutro Biopharma's CEO on ADCs, non-cell protein synthesis, and more
#4. Verve Therapeutics' CEO on today's gene editing clinical trial pause
#5. Daphne Zohar on becoming the CEO of Seaport Therapeutics and a $100M series A